Pfizer CEO Albert Bourla announced that major pharmaceutical companies are ready to work with the Trump administration to ...

Investor sentiment has been adversely affected by worries regarding the company’s drug pipeline. Nonetheless, we believe PFE ...

U.S. drugmaker Pfizer raised its full-year profit forecast on Tuesday after reporting better-than-expected results for the ...

Pfizer is starting to execute on its turnaround plan and drug pipeline. 10 stocks we like better than Pfizer › Shares of the ...

Pfizer stock rises after a strong Q2, boosted by cost savings, pipeline progress, and an upgraded 2025 profit outlook.

Pfizer (PFE) topped second quarter expectations, but looming Trump-era pharmaceutical tariffs remain a concern. Pfizer CEO ...

Pfizer (PFE) reported a beat in second quarter earnings Tuesday, and reaffirmed its 2025 guidance of between $61 to $64 ...

Pfizer stock rose after the drugmaker posted adjusted earnings came in at 78 cents a share on revenue of $14.7 billion, ...

As investors and industry watchers juggle the twin possibilities of pharmaceutical import tariffs and potential drug pricing ...

While the drugmaker reaffirmed its 2025 revenue guidance of $61bn to $64bn, it raised its full-year 2025 profit outlook. Pfizer now expects to earn $2.90 to $3.10 per share, compared with its previous ...

Pfizer's Albert Bourla told investors that major drugmakers are "ready to roll up their sleeves" and build out more direct-to ...

Pfizer CEO Albert Bourla is expected at a pro-Trump fundraiser on Friday, sources told CBS News, one day after the president ...